LYNCHBURG, Va.--(BUSINESS WIRE)--BWX Technologies, Inc. (NYSE: BWXT) announced today that subsidiary BWXT ITG Canada, Inc., having received approval from the U.S. Food and Drug Administration (FDA) on its abbreviated new drug application for its generic version of Indium In-111 Oxyquinoline Solution, is now making the product available for sale in the United States.
Indium In-111 Oxyquinoline is a diagnostic radiopharmaceutical intended for radiolabeling autologous leukocytes.
“BWXT is extremely pleased to introduce this important diagnostic imaging product to the medical isotope market,” said Rex Geveden, BWXT’s president and chief executive officer. “We are strongly committed to this exciting market and look forward to broadening our product portfolio in the months and years to come.”
“This approval of Indium In-111 Oxyquinoline will position us to continue supporting the patients and medical community who can benefit from having access to this radiopharmaceutical,” said Tom Burnett, BWXT ITG Canada, Inc. vice president and general manager. “This is BWXT ITG Canada, Inc.’s first generic product to market, and I’m very proud of our team’s development efforts that made today’s milestone possible.”
Indium In-111 Oxyquinoline Solution is available in the United States by visiting our website here. or by calling 1-800-267-6211. Further details on BWXT’s Indium In-111 Oxyquinoline Solution can be found on our website here.
Forward Looking Statements
BWXT cautions that this release contains forward-looking statements, including statements relating to the production, performance, timing, impact and value of Indium In-111 Oxyquinoline, as well as future product offerings. These forward-looking statements involve a number of risks and uncertainties, including, among other things, changes in competition, market demand and production delays in Indium In-111 Oxyquinoline. If one or more of these or other risks materialize, actual results may vary materially from those expressed. For a more complete discussion of these and other risk factors, please see BWXT’s annual report on Form 10-K for the year ended December 31, 2018 and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. BWXT cautions not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and undertakes no obligation to update or revise any forward-looking statement, except to the extent required by applicable law.
Headquartered in Lynchburg, Va., BWX Technologies, Inc. (NYSE: BWXT) is a leading supplier of nuclear components and fuel to the U.S. government; provides technical and management services to support the U.S. government in the operation of complex facilities and environmental remediation activities; and supplies precision manufactured components, services and fuel for the commercial nuclear power industry. With approximately 6,350 employees, BWXT has 11 major operating sites in the U.S. and Canada. In addition, BWXT joint ventures provide management and operations at more than a dozen U.S. Department of Energy and NASA facilities. Follow us on Twitter at @BWXTech and learn more at www.bwxt.com.